Linear Endosonography for the Assessment of Sarcoidosis Stage O (LASSO)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01383226|
Recruitment Status : Unknown
Verified June 2011 by Universitaire Ziekenhuizen Leuven.
Recruitment status was: Active, not recruiting
First Posted : June 28, 2011
Last Update Posted : October 10, 2013
|Condition or disease||Intervention/treatment||Phase|
|Lymphadenitis||Procedure: Thoracic endosonography||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||100 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||CT Enlarged Mediastinal/Hilar Lymph Nodes Not Visible on Chest X-ray in the Non Cancer Patient : Diagnosis and Clinical Implications Using Endobronchial or Esophageal Ultrasound Controlled Needle Aspiration E(B)US-NA|
|Study Start Date :||June 2011|
|Estimated Primary Completion Date :||October 2013|
|Estimated Study Completion Date :||April 2014|
Thoracic endosonography, either endobronchial or esophageal ultrasound controlled needle aspiration, is a minimally invasive diagnostic technique.
Procedure: Thoracic endosonography
Thoracic endosonography is a minimal invasive diagnostic intervention
- Diagnostic sensitivity [ Time Frame: One year ]The primary aim is to assess the nature and prevalence of abnormal findings in samplings obtained during E(B)US-NA in the non-cancer patient with CT enlarged mediastinal/hilar lymph nodes that are not visible on chest X-ray.
- Clinical impact. [ Time Frame: One year ]As secondary aims, the clinical implications of E(B)US-NA findings will be assessed, in particular the number of cases where a specific treatment is initiated.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01383226
|Hopital Saint-Pierre Bruxelles|
|Centre Hospitalier Universitaire Charleroi|
|Ghent University Hospital|
|Ghent, Belgium, 9000|
|University Hospitals Leuven|
|Leuven, Belgium, 3000|
|Heilig Hart Ziekenhuis Roeselare|
|Université Catholic Louvain|
|Principal Investigator:||Christophe A Dooms, MD, PhD||University Hospitals Leuven|
|Principal Investigator:||Vincent Ninane, MD, PhD||Hopital Saint-Pierre Brussels|